22:57:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-07-11 Kvartalsrapport 2024-Q2
2024-06-28 Årsstämma 2024
2024-06-12 X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 Kvartalsrapport 2024-Q1
2024-02-27 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-07-03 Extra Bolagsstämma 2023
2023-06-13 Årsstämma 2023
2023-05-24 X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-26 X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-27 X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-03 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt övrig grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Bolaget grundades 2008 och har huvudkontoret i Uppsala.
2023-12-28 11:50:00

Q-linea AB (publ) (OMX:QLINEA) today announces that the company has installed its first two systems in the United States, offering selected sites access to ASTar, pending marketing authorization and commercial launch.

“We see that we are nearing marketing approval and commercial launch. As part of the launch preparations, we are now installing two systems giving potential customers the opportunity to get to know the system better. The systems are installed at two very reputable sites, which we hope will be some of the first to order the system once it is commercially available”, said Jonas Jarvius, CEO of Q-linea. 

“We are excited to begin the next phase of our journey of introducing Q-linea and ASTar in the US. Interest by prominent laboratory and clinical thought leaders across the US has been strong for evaluating the potential impacts of rapid AST in their healthcare systems. As we prepare for commercial launch, we are excited to gain further insights into the potential impacts our rapid AST solution can have on sepsis and patient management”, said Jim Kathrein, VP of Commercial Operations for Q-linea Inc. 

The systems are installed for research use only (RUO).

About ASTar Instruments and ASTar BC G-Kit 
ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.  
 
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.